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In 1996, 2,771 cases of pertussis were
reported to the Inspectorate of Health in the
Netherlands (population 15 million), compared
with 319 cases in 1995. With epidemic cycles
expected every 3 to 5 years and a recent outbreak
in 1994, this rise was unexpected (1). After the
introduction of pertussis immunization with a
whole-cell vaccine in the National Immunization
Program (1952), the incidence of pertussis in the
Netherlands decreased significantly. Children
are immunized at ages 3, 4, 5, and 11 months
with a diphtheria, tetanus, pertussis, and inacti-
vated polio vaccine (DTP-IPV), and vaccine
coverage for pertussis, for at least three immuni-
zations, is 96% at the age of 12 months. Until the
1980s, the incidence of pertussis seemed very
low, because only incidental cases were reported.
However, in the last two decades, pertussis has
been endemic, and epidemic peaks have appeared.
The surveillance of pertussis is based mainly
on notification, which was made obligatory by
law in 1976. Because the availability and inter-
pretation of serologic tests changed in the 1980s
and the absence of a clear case definition for
notification seemed to have influenced surveil-
lance, a restrictive case definition that included cri-
teria for laboratory diagnosis was introduced in
1988. Therefore, we have limited this report to
notification data from 1989 onwards. The annual
incidence of pertussis notification from 1989 to
1995 is shown in Figure 1. In this period, the case
definition includes defined clinical symptoms and
laboratory confirmation. The clinical symptoms
are a serious cough lasting more than 2 weeks or
cough attacks or cough followed by vomiting in
combination with at least one of the following
symptoms/findings: apnea, cyanosis, characteristic
cough with whooping, subconjunctival bleeding,
leukocytosis, or contact with a person with conf-
irmed or suspected pertussis in the previous 3
weeks. Laboratory confirmation is defined as
either positive culture of Bordetella pertussis or
Bordetella parapertussis or positive two-point
serology, i.e., the finding of a significant rise (> 4-
fold) of IgG antibodies against pertussis toxin
and/or IgA antibodies against B. pertussis in
paired sera. The case definition is highly specific,
but results in significant underreporting.
Pertussis in the Netherlands: an Outbreak
Despite High Levels of Immunization
with Whole-Cell Vaccine
Figure 1. Annual incidence of pertussis estimated from
notification by registration date, 1989–1995
We compared the number of cases reported per
4-week period in 1996 with the number reported in
1994, the year with the highest incidence in
recent years (Figure 2). It appears that an unex-
pectedly large number of pertussis cases was
reported (18 per 100,000) in 1996. The reports came
from all over the country. No geographic clus-
tering was observed, even in regions with pockets
of low vaccination coverage or at the borders of
In 1996, a sudden increase in pertussis incidence was reported in the Netherlands
(2.1 per 100,000 in 1995, 18 per 100,000 in 1996). Although not all potential surveillance
artifacts could be excluded, it is highly probable that the data reflect a true outbreak.
However, the cause of this increase has not yet been determined. Further research is
directed to the severity of disease and a possible mismatch between the vaccine and
the circulating Bordetella strains.176 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
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the country (close to Germany, where vaccination
coverage for pertussis is low).
The age distribution of patients in 1989 to
1996 shows a significant decrease in the propor-
tion of infants less than 1 year old (from 21% in
1989 to 7% in 1996) and a significant increase in the
proportion of 1- to 4-year-old children (from 21% in
1989 to 30% in 1996). A significant decrease (from
42% in 1989 to 30% in 1995) was also observed in
5- to 9-year-old children; however, in 1996, the pro-
portion increased to 39%. No changes were
observed in the 10- to 14- and 15- to 19-year-old
groups, whereas the proportion of patients 20 years
old or older increased from 5% to 11% (Table).
(Figure 3). Calculation of incidence according to
vaccination status was deliberately restricted to
ages 1 to 4 years and 5 to 9 years (vaccine coverage
estimated at 96%) for methodologic reasons. The
changes in age-specific incidence over the years
for vaccinated and unvaccinated children are iden-
tical for 1989 to 1993. However, from 1994 to 1996,
and particularly in 1996, the incidence among vac-
cinated 1- to 4-year-olds was considerably higher
than in 1989 and 1990, the years with the highest
incidence in 1989 to 1993. In unvaccinated
children, the incidence in 1994 and 1995 was
lower than in 1989 and 1990. The difference in
incidence between the period 1989 to 1990 and
the year 1996 was much smaller in unvaccinated
than in vaccinated persons. A similar discrepancy
can be seen in the 5- to 9-year-old group.
In view of the increase in pertussis reporting
in 1996, the first issue to be addressed was
whether this reporting reflected a true increase
in pertussis incidence or was a surveillance arti-
fact. If considerable underreporting is assumed,
an increase due to improved compliance to the
notification system or increased alertness should
be considered. However, in the first two quarters
of 1996, there is no apparent reason for such an
assumption. Nonetheless, after the first reports
of the observed rise, both publicity and increased
awareness of the disease by physicians and
patients might have influenced reporting.
Serodiagnosis for the country as a whole is
done by a single reference laboratory at the
National Institute of Public Health and the
Environment; thus, the data provided by the
laboratory can be used for nationwide surveillance.
Furthermore, the reference laboratory collects
strains of B. pertussis from regional public health
laboratories, and the number of strains received
also reflects the epidemic curve. The epidemiologic
curve derived from these sources over the past
years is consistent with the notification data.
Since laboratory confirmation is part of the
case definition, changes in serodiagnostic practice
might have influenced notification. Frequently,
no conclusive results are obtained from serology:
a second serum sample may not be submitted, or
the first serum sample may be taken late after
onset of disease, thereby missing the dynamic
phase of the immunoresponse. Recently, cut-off
values for antibody titers characteristic for the
acute immunoresponse after natural infection with
B. pertussis have been determined by comparing
the titer distribution in the healthy population,
Figure 2. Number of cases reported by registration date,
1994 and 1996 (4-week periods).
Table. Age distribution (percentages) pertussis notification
in 1989 to 1996
Age 1989 1990 1991 1992 1993 1994 1995 1996
0   21   21   23   21   24   16   13     7
1-4   21   21   26   19   27   34   33   30
5-9   42   37   34   30   26   32   30   39
10-14   10    9   10   17   12     8   10   11
15-19     1    2     2     2     1     1     1     2
‡20     5    9     6    11   10     8   12   11
Unknown     0    0     1      1     0     1     1     0
Total (n) 434 471 164  169 294 536 319 2,771
n
u
m
b
e
r
/
1
0
0
,
0
0
0
weeks
1-4
5-8
9-12
13-16
17-20
21-24
25-28
29-32
33-36
37-40
41-44
45-48
49-50
  —— 1994 - - - -1996
Whereas the average vaccine coverage did not
change, the proportion of vaccinated patients in-
creased from 55% in 1989 to 85% in 1996. In all age
groups, except that of 6- to 11-month old infants,
the proportion of vaccinated patients is higher in
the years 1994 to 1996 than in 1989 to 1993.
We estimated the annual incidence of
pertussis for vaccinated and unvaccinated children
ages 1 to 4 and 5 to 9 years, on the basis of
reporting by registration date (1989 to 1996)177 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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in recently vaccinated children, and in sera
longitudinally collected after natural infection.
Since 1993, high titers in acute-phase sera are
reported to be “suggestive for recent infection
with Bordetella pertussis” (2). It can be imagined
that such cases are reported, albeit not strictly in
accordance with the case definition.
To exclude the possibility that the rise in noti-
fication was the result of reporting cases diagnosed
with positive one-point serology only, we linked
the notification and serodiagnosis databases. (The
data were taken from January 1993 to September
1996.) Special permission to link the databases was
given by the Inspectorate of Health. It appeared
that some notification was based on positive one-
point serology as early as 1993, and this proportion
increased from 20% in 1993 to 33% in 1994. It
remained at this level in the subsequent years.
Thus, the 1996 increase in notification cannot be
attributed to this change in serodiagnostic practice.
Our surveillance data suggest a decrease in
vaccine efficacy, but estimation of vaccine efficacy
from surveillance data should be interpreted
with caution. However, there are no indications
of significant bias from physicians’ perceptions of
vaccine efficacy that could have caused selective
reporting of vaccinated patients; a higher proba-
bility of a positive serologic test  result due to
priming in vaccinated persons; or misclassification
of cases with respect to vaccination status.
Although not all potential surveillance artifacts
could be excluded, it is highly probable that the
surveillance data reflect a true pertussis outbreak.
The outbreak could have been caused by 1) decrease
in vaccination coverage, 2) decrease in vaccine
quality, 3) interference with other vaccines, 4) changes
in circulating strains of B. pertussis that are not
covered by vaccine-induced immunity, or 5) a com-
bination of these factors. A decrease in vaccina-
tion coverage has not been observed in the
(accurate) reporting system. The whole-cell vaccine
used was produced in the National Institute of
Public Health and the Environment and meets in-
ternational standards. There was no sign of a
gradual deterioration of vaccine quality as determined
for product release by the mouse protection test.
In April 1993, vaccination against Haemo-
philus influenzae type b (Hib) was added to the
immunization program. The polyribosylribitolphos-
phate tetanus toxoid conjugated vaccine (PRP-T)
was administered simultaneously with the DTP-
IPV, although on different limbs. Interference of
Hib vaccination with the immunoresponse to
pertussis vaccine has been described (3). In a
prospective serologic study on the potential inter-
ference in the Netherlands, this effect was not
observed (4). Furthermore, the increase of pertus-
sis in 5- to 9-year-old vaccinated children, who
never received Hib vaccine, was similar to the
increase in the 1- to 4-year-old age group (Figure 3).
Decreased vaccine efficacy due to interference of
Hib vaccination is, therefore, very unlikely.
Molecular typing of B. pertussis isolates
collected since 1945 indicated a shift in population
structure, possibly due to the introduction of
whole-cell vaccine (5). Further, antigenic variants
of B. pertussis distinct from the strains incor-
porated in the vaccine appear to have emerged
(6). It might be possible that circulating strains of
B. pertussis have become less sensitive to vaccine-
induced immunity. The abrupt increase in the
proportion of vaccinated patients reported in all
age groups suggests such a change.
Data from other countries in Europe indicate
that the pertussis epidemic is restricted to the
Netherlands. However, a resurgence of pertussis
has been noted in the United States since the late
Figure 3. Estimated incidence of pertussis for unvacci-
nated and vaccinated children aged 1-4 years and 5-9
years based on notification records and assuming a cov-
erage of 96% for the entire population.178 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
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1980s and in Canada since 1991. No single factor
has been found to explain this resurgence (7-10).
The decrease in pertussis notification in the
Netherlands at the end of 1996 may indicate a
seasonal variation in incidence. The 1996 data,
including those on hospital admissions, are still
being analyzed. These data will give insight into
the severity of the pertussis epidemic among
infants. Protection of these infants is the main
reason for pertussis vaccination. In January
1997, active (monthly) surveillance by pedia-
tricians of cases among hospitalized children was
added to the routine surveillance based on
notification and laboratory surveillance.
A prospective study is being considered to
assess efficacy of the whole-cell vaccine, including
differentiation of severity of illness and number
of immunizations received, if the outbreak con-
tinues. Cooperative studies to determine the
distribution of restriction fragment length polymor-
phism types and antigenic variants of B. pertussis
in various countries in Europe, Asia, and North
America are under way. Also, the immunogenicity
of the Dutch whole-cell vaccine is being assessed:
whether it has changed over time and how it
compares to published immunogenicity data of
whole-cell vaccines with known, prospectively
determined, vaccine efficacy (11).
In conclusion, in the Netherlands a sudden
increase of pertussis notification has been
observed, which seems to reflect a true increase in
incidence. Nevertheless, the cause of this increase
has not been definitively determined. A possible
mismatch between the vaccine and the circulating
Bordetella strains is being investigated.
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